Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Universities of Oxford and Birmingham joined forces with colleagues from seven NHS organisations at a workshop in Oxford to discuss an innovative new approach to inflammatory disease research.

A diverse crowd of discovery scientists, clinicians and healthcare professionals met earlier this month at St Anne's College, Oxford, for the first Arthritis Therapy Acceleration Programme (A-TAP) workshop.

A-TAP was launched in 2017 to speed up the development of new therapeutics for inflammatory disease. The initiative brings broad expertise from the Universities of Oxford and Birmingham together with healthcare professionals and their patients, from seven NHS centres across the M40 corridor.

Setting the tone, A-TAP lead and Director of Clinical Research at the Kennedy Institute, Professor Chris Buckley said "These are exciting times for experimental medicine. We have new drugs and new ways of designing clinical trials and combining the two in this innovative way will speed up the delivery of medicines to those who need it the most."

In his opening remarks, Prof Buckley also highlighted one of A-TAP's key goals - to build infrastructure and expertise to enable "basket trials", where new drugs are tried out in multiple diseases simultaneously. The drugs will be assessed not only on their impact on the symptoms of diseases, but crucially also on how they change the processes within the cells linked to the disease.

This is particularly relevant for complex inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, where common defects in immune pathways can underlie different types of disease.

A-TAP will initially focus on four inflammatory diseases: rheumatoid arthritis, Sjogren's Syndrome, inflammatory bowel disease and spondyloarthropathy. Workshop participants discussed how patient tissue samples and NHS data are being analysed over time to better understand the causes of disease onset and progression. This will facilitate clinical trials that select subgroups of patients most likely to benefit from therapy across disease types. This "stratified pathology" approach is already used in the cancer field with promising results.

The workshop also considered trial design, data collection and storage, and appropriate biological endpoints to measure how drugs affect the underlying cause of disease in tissues.

A-TAP is supported by a £7M funding award from the Kennedy Trust for Rheumatology Research. It benefits from basic science expertise at the Kennedy Institute, NDORMS (Oxford) and translational research capabilities at the Botnar Research Centre, NDORMS (Oxford) and the Institute of Translational Medicine (University of Birmingham).

Researchers or industry partners interested in learning more about A-TAP should contact A-TAP Operations Manager Dr Claire Potter.

IN PARTNERSHIP WITH

Institute of Translational Medicine (University of Birmingham)

FUNDED BY

Kennedy Trust

Similar stories

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

Defining the role of resident memory B cells in the fight against influenza

Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

The COVID-19 Multi-omic Blood Atlas (COMBAT) has identified blood hallmarks of COVID-19 involving particular immune cell populations and their development, components of innate and adaptive immunity, and connectivity with the inflammatory response.

Professor Chris Buckley joins the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters "good" macrophage behaviour within the vessel wall.